Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Botanova ads scrutinized

This article was originally published in The Tan Sheet

Executive Summary

The U.K. Medicines and Healthcare products Regulatory Agency upholds three advertising complaints filed last fall against German pharmaceutical company Pascoe Pharmazeutische Praparate GmbH. The complaints allege marketing for Botanova (St. John's wort, passion flower and valerian) misleads consumers. The British Herbal Medicine Association and Schwabe Pharma complained Pascoe ads inappropriately touted Botanova has improved efficacy over other products. The claims violate U.K. ad requirements for traditional herbal medicines. BHMA also complained that Botanova press materials incorrectly said the product is not associated with drug-drug interactions. Pascoe revised the materials and confirmed future marketing material will comply with the U.K. requirements for advertising of registered traditional herbal medicines, according to notices MHRA posted July 17

You may also be interested in...

China Detains Legend Biotech CEO, Exposes Genetic Material Minefield

Frank Zhang, co-founder and chair of the Hong Kong-listed Chinese biotech Genscript, parent of Nasdaq-listed cell therapy star, Legend Biotech, has been detained by Chinese authorities, along with four employees.

QUOTED. 23 September 2020. US FDA

Tests used to detect cytomegalovirus in organ transplant patients may face an easier path to market under a proposed rule that the US Food and Drug Administration released on 18 September. See what the regulatory agency said about it here.

Six Pharma CEOs To Testify In House as Democrats, Trump Compete For Attention On Drug Pricing

While neither party is likely to make any big policy changes this year, the action from both sides of the aisle indicates politicians still see going after pharma as a winning issue with voters even as polls show voters are focused elsewhere. 





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts